New drug BDC-4182 targets stomach cancer by waking up the immune system

NCT ID NCT06921837

Recruiting now Disease control Sponsor: Bolt Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will enroll 122 participants to check safety and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BDC-4182, an immune-stimulating antibody conjugate that targets claudin 18.2 on cancer cells and activates the immune system
What this could lead to: If successful, this could lead to a new treatment option for advanced gastric and gastroesophageal cancers that have stopped responding to standard therapies.
What could go wrong: This is an early first-in-human trial, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates